2016-01-012 + 2016-01-013 - ONCO-SELEC - Oncoselective mechanism for gene or viral therapy
Contacts
AO
CH
Acronim & Gínjol codes
ONCO-SELEC
2016-01-012 + 2016-01-013
Main technology offer
New tool designed to fight cancer based on a novel mechanism that may be applied in optimising the efficacy of genetic therapies. Mechanism that can be implemented in almost any gene or virus-based therapy, both existing or in development, providing higher selectivity of cancerous tissues.
Ownership
Barcelona, Spain
2005
Institut de Recerca Biomèdica (IRB Barcelona)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
Market Data
Problem: High toxicity of genetic therapies for cancer treatment Solution: The objective is to design genetic therapies with attenuated toxicity and to improve the safety and efficacy of gene and viral therapies. The mechanism of action performs as a dual regulation system: in tumor cells our mechanism acts as an activator and in non-tumor cells as a repressor. Our proprietary technology provides a novel approach that can be combined with existing oncoselective methods and, due to its features, it does not affect vector fitness, oncolytic competence and/or delivery.
0
0
0
Licensing out or codevelopment
New tools to provide vectors specificity for cancer cell lines for oncolytic therapies.
Not applicable
Technology Status
Novel short sequence that provide cell cancer specificity
Patent abandoned
Patent and technology abandoned
Additional information
ONCO-SELEC is a mechanism that can be implemented in almost any gene or virus-based therapy, both existing or in development, providing higher selectivity of cancerous tissues.